Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 37

Results For "company"

4861 News Found

Stratasys completes US rollout of RadioMatrix 3D-printed imaging support material
Healthcare | December 04, 2025

Stratasys completes US rollout of RadioMatrix 3D-printed imaging support material

The technology is intended to support imaging-based training, protocol optimisation and surgical planning


Jacobio combo delivers 71% ORR, sets stage for first SHP-2–based NSCLC therapy
Clinical Trials | December 04, 2025

Jacobio combo delivers 71% ORR, sets stage for first SHP-2–based NSCLC therapy

Jacobio stated that these findings underscore the potential of glecirasib and sitneprotafib


Aptar acquires Brazilian pharma packaging firm Sommaplast
Packaging | December 04, 2025

Aptar acquires Brazilian pharma packaging firm Sommaplast

Sommaplast’s portfolio includes closures, droppers, dispensers and dosing cups, supporting a broad range of oral dosing applications


Aelis Farma gets EMA nod for phase 2B trial of AEF0217 in down syndrome
Biopharma | December 04, 2025

Aelis Farma gets EMA nod for phase 2B trial of AEF0217 in down syndrome

AEF0217 is a first-in-class CB1 receptor signaling-specific inhibitor


ZIM Laboratories receives CDSCO approval for Naproxen + Esomeprazole capsules
Drug Approval | December 04, 2025

ZIM Laboratories receives CDSCO approval for Naproxen + Esomeprazole capsules

Grant of Permission to manufacture and market FDC of Naproxen Delayed Release and Esomeprazole capsule (375mg/500mg + 20mg/20mg)


Jubilant Pharmova appoints Daniel J. O Connor as CEO of Jubilant Therapeutics
People | December 04, 2025

Jubilant Pharmova appoints Daniel J. O Connor as CEO of Jubilant Therapeutics

O'Connor brings over 30 years of leadership experience in the biotechnology and oncology sectors


Merck unveils first human data for Alzheimer’s candidates
Clinical Trials | December 03, 2025

Merck unveils first human data for Alzheimer’s candidates

The company also revealed that MK-2214 has received Fast Track Designation from the U.S. Food and Drug Administration


Celltrion gets Health Canada nod for Eylea biosimilar Eydenzelt
Clinical Trials | December 03, 2025

Celltrion gets Health Canada nod for Eylea biosimilar Eydenzelt

Health Canada’s approval was based on a comprehensive evaluation of analytical, nonclinical, and clinical data


EIB, Angelini Ventures team up to pump €150 million into European biotech, digital health startups
Startup | December 03, 2025

EIB, Angelini Ventures team up to pump €150 million into European biotech, digital health startups

Angelini Ventures has already invested €125 million in 22 startups